Skip to main content
. Author manuscript; available in PMC: 2016 Jan 1.
Published in final edited form as: J Thromb Haemost. 2014 Dec 11;13(1):2–9. doi: 10.1111/jth.12787

STROBE Statement–checklist of items that should be included in reports of observational studies

Item
No
Recommendation Reported
on page
Title and abstract 1 (a) Indicate the study's design with a commonly used term in the title
or the abstract
1
(b) Provide in the abstract an informative and balanced summary of
what was done and what was found
2
Introduction
Background/rationale 2 Explain the scientific background and rationale for the investigation
being reported
3
Objectives 3 State specific objectives, including any prespecified hypotheses 3
Methods
Study design 4 Present key elements of study design early in the paper 3-4
Setting 5 Describe the setting, locations, and relevant dates, including periods of
recruitment, exposure, follow-up, and data collection
3,4,6
Participants 6 (a) Cohort study—Give the eligibility criteria, and the sources and
methods of selection of participants. Describe methods of follow-up
Case-control study—Give the eligibility criteria, and the sources and
methods of case ascertainment and control selection. Give the rationale
for the choice of cases and controls
Cross-sectional study—Give the eligibility criteria, and the sources and
methods of selection of participants
3,4,6
(b) Cohort study—For matched studies, give matching criteria and
number of exposed and unexposed
Case-control study—For matched studies, give matching criteria and
the number of controls per case
NA
Variables 7 Clearly define all outcomes, exposures, predictors, potential
confounders, and effect modifiers. Give diagnostic criteria, if
applicable
4-6
Data sources/
measurement
8* For each variable of interest, give sources of data and details of
methods of assessment (measurement). Describe comparability of
assessment methods if there is more than one group
4-6
Bias 9 Describe any efforts to address potential sources of bias
Study size 10 Explain how the study size was arrived at
Quantitative variables 11 Explain how quantitative variables were handled in the analyses. If
applicable, describe which groupings were chosen and why
6,7
Statistical methods 12 (a) Describe all statistical methods, including those used to control for
confounding
6,7
(b) Describe any methods used to examine subgroups and interactions 6,7
(c) Explain how missing data were addressed 6
(d) Cohort study—If applicable, explain how loss to follow-up was
addressed
Case-control study—If applicable, explain how matching of cases and
controls was addressed
Cross-sectional study—If applicable, describe analytical methods
taking account of sampling strategy
6
(e) Describe any sensitivity analyses NA
Results
Participants 13* (a) Report numbers of individuals at each stage of study—eg numbers
potentially eligible, examined for eligibility, confirmed eligible, included in the
study, completing follow-up, and analysed
6
(b) Give reasons for non-participation at each stage 6
(c) Consider use of a flow diagram ---
Descriptive
data
14* (a) Give characteristics of study participants (eg demographic, clinical, social)
and information on exposures and potential confounders
Table 1
(b) Indicate number of participants with missing data for each variable of
interest
Table 1
(c) Cohort study—Summarise follow-up time (eg, average and total amount) 7
Outcome data 15* Cohort study—Report numbers of outcome events or summary measures over
time
7
Case-control study—Report numbers in each exposure category, or summary
measures of exposure
NA
Cross-sectional study—Report numbers of outcome events or summary
measures
NA
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates
and their precision (eg, 95% confidence interval). Make clear which
confounders were adjusted for and why they were included
Tables 2
and 3
(b) Report category boundaries when continuous variables were categorized 7
(c) If relevant, consider translating estimates of relative risk
into absolute risk for a meaningful time period
Table 2
Other analyses 17 Report other analyses done—eg analyses of subgroups and interactions, and
sensitivity analyses
8
Discussion
Key results 18 Summarise key results with reference to study objectives 8
Limitations 19 Discuss limitations of the study, taking into account sources of potential bias or
imprecision. Discuss both direction and magnitude of any potential bias
11
Interpretation 20 Give a cautious overall interpretation of results considering objectives,
limitations, multiplicity of analyses, results from similar studies, and other
relevant evidence
8-12
Generalisability 21 Discuss the generalisability (external validity) of the study results 11-12
Other information
Funding 22 Give the source of funding and the role of the funders for the present study
and, if applicable, for the original study on which the present article is based
12-13
*

Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and crosssectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.

Von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007; 370:1453-7

HHS Vulnerability Disclosure